Regeneron Pharmaceuticals (REGN) Earnings Date & Reports
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation... Show more
REGN is expected to report earnings to rise 14.57% to $10.85 per share on July 30
Regeneron Pharmaceuticals (REGN) Q1 2026 Earnings Recap: Dupixent Drives 19% Revenue Surge
Key Takeaways
- Total revenues climbed 19% year-over-year to $3.6 billion, surpassing consensus estimates of $3.48 billion.+Tops+Q1+EPS+by+50c,+Beats+on+Revenue/26387485.html)
- Non-GAAP diluted EPS rose 15% to $9.47, beating expectations around $8.96-$9.07.
- Sanofi collaboration revenue, boosted by Dupixent, jumped 36% to $1.605 billion.
- U.S. EYLEA family sales fell 10% to $941 million due to competition and patient shifts to EYLEA HD.
- Company authorized a new $3 billion share repurchase program and declared a $0.94 quarterly dividend.
- Shares dropped about 6% in post-earnings trading amid concerns over EYLEA trends and guidance tweaks.
Earnings Context and Why It Matters
Regeneron Pharmaceuticals' Q1 2026 earnings provide critical insights into its diversified portfolio amid evolving competitive dynamics in ophthalmology and robust growth in immunology and oncology. The biotech giant has navigated EYLEA sales pressures from biosimilars and launches like EYLEA HD, while collaborations such as Dupixent with Sanofi continue to fuel top-line expansion. Investors closely watch these results for signals on product lifecycle management, pipeline progress, and capital returns, especially as Regeneron balances heavy R&D investments with shareholder-friendly moves like buybacks. This quarter underscores the company's resilience in a high-stakes pharma landscape.
Total revenues reached $3.605 billion, a 19% increase from $3.0 billion in Q1 2025, driven primarily by higher collaboration profits from Dupixent and growth in oncology products. Net product sales totaled $1.535 billion, up 8%, with Libtayo global sales soaring 54% to $438 million on expanded indications. U.S. EYLEA HD sales more than doubled to $468 million, but total EYLEA family U.S. sales declined 10% to $941 million due to competitive pressures and transitions.
GAAP diluted EPS was $6.75, down from $7.27, reflecting a $0.82 IPR&D (in-process research and development) charge. Non-GAAP diluted EPS of $9.47 rose 15% year-over-year, exceeding consensus. Sanofi collaboration revenue jumped 36% to $1.605 billion, with Regeneron's Dupixent profit share at $1.451 billion, up from $1.018 billion.
Guidance for full-year 2026 saw minor adjustments: GAAP gross margin on product sales lowered to 77%-78%, and cost of collaboration and other manufacturing (COCM) raised slightly to $955-$1,035 million. R&D expenses remain $6.45-$6.68 billion (GAAP). Cash and securities stood at $18.5 billion.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research process.
Market Reaction and Investor Sentiment
Despite beating revenue and non-GAAP EPS estimates, REGN shares fell approximately 6% on April 29, closing around $686. The sell-off reflected investor disappointment with the EYLEA sales decline, softer-than-expected gross margins, and conservative guidance tweaks, overshadowing Dupixent and Libtayo strengths. Sentiment remains mixed, with focus shifting to EYLEA HD uptake and oncology momentum.
Forward Outlook and Key Factors to Monitor
Investors should track EYLEA HD adoption, as FDA approvals for longer dosing intervals in wet AMD (wAMD) and diabetic macular edema (DME) could stabilize ophthalmology sales. Pre-filled syringe manufacturing resubmission to the FDA is pending a Q2 2026 decision, potentially easing supply constraints.
In oncology, Libtayo's momentum and fianlimab Phase 3 data in melanoma (expected Q2 2026) are pivotal. Dupixent label expansions into chronic spontaneous urticaria (CSU) in children and aspirin-exacerbated respiratory disease (AFRS) broaden its market, supporting collaboration revenue.
Pipeline catalysts include FDA decisions for cemdisiran in myasthenia gravis (Q4 2026), garetosmab in fibrodysplasia ossificans progressiva (FOP) by August 2026, and ongoing Phase 3 trials in obesity and cancer-associated VTE. With $18.5 billion in cash, $3 billion buyback authorization, and steady dividends, Regeneron maintains flexibility for R&D and returns. Monitor gross margins, IPR&D impacts, and competitive pressures in eye disease treatments.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Advertisement
General Information
a developer of medicines for the treatment of serious medical conditions
Industry Biotechnology